Supreme court to finally rule on ‘Galvus’ patent dispute
By Kim, Jin-Gu | translator Alice Kang
21.10.21 06:00:50
가나다라
0
Supreme court announced that it will make a ruling on the 28th… mixed rulings at 1st and 2nd trial
Interest rises on whether this would be the first case of overcoming ‘the extended term of a patent’
The 4-year long patent dispute over the patent of the anti-diabetic DPP-4 inhibitor ‘Galvus (vildagliptin)’ will finally come to an end at the Supreme Court on the 28th.
Industry officials believe that the Supreme Court’s decision may affect and modify the overall patent strategies of generic companies in the coming future. If the Supreme Court rules in favor of Ahn-Gook Pharmaceuticals, this will greatly increase the number of challenges filed on substance patents of original drugs, which have been considered impregnable.
◆Will the first ‘invalidation of substant patent extension’ case be born?
According to industry sources on the 20th, the Supreme Cour
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)